FDA approves TherapeuticsMD's menopause drug

FDA has approved estradiol and progesterone (Bijuva—TherapeuticsMD) capsules for the treatment of menopause symptoms such as hot flashes, sleep disturbances, and night sweats. The drug's maker expects it to be available in the second quarter of 2019. Brokerage Cowen & Co. forecast earlier this month that the therapy could bring in peak U.S.

FDA has approved estradiol and progesterone (Bijuva—TherapeuticsMD) capsules for the treatment of menopause symptoms such as hot flashes, sleep disturbances, and night sweats. The drug's maker expects it to be available in the second quarter of 2019. Brokerage Cowen & Co. forecast earlier this month that the therapy could bring in peak U.S. sales of more than $900 million by 2027. The drug includes a boxed warning for cardiovascular disorders, breast cancer, endometrial cancer, and probable dementia.